Obermatt
See Similar Stocks →

Veru

NAQ:VERU · US92536C2026
PharmaceuticalsX-Small

360° View

23
Price/Sales31
Price/Earnings44
Price/Book43
Dividend Yield1
Revenue Growth33
Profit Growth60
Capital Growth42
TSR 52w12
Leverage42
Liquidity75
Refinancing28
Combined15
Analyst Opinions100
Pro Holdings13
Opinion Changes50
Market Pulse13

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded1971
Employees29
Websiteverupharma.com
ISINUS92536C2026
Last UpdateApr 2, 2026
Index & Theme
RespiratoryWomen's HealthObesityInfectious DiseasesOncologyBiopharmaBiotechnologyMedical

Description

Veru Inc. operates as a late clinical stage biopharmaceutical company. The company focuses on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Drug Development Program The…

Analysis

Veru's 360° View rank of 23 places it among the weakest overall — better than 23% of its true peers.

It's growing slowly (32) and on the expensive side (29). On safety it is carrying more balance-sheet risk (30), and the market shows muted sentiment (49). Taken together, its Combined rank of 15 reads as among the weakest overall.

360° rank · history

1007550250
23
2023202420252026

All-time high

54

Jan 2025

All-time low

1

Jan 2024

Average rank

26

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
31
1
11
33
Price/Earnings
44
22
22
22
Price/Book
43
47
35
62
Dividend Yield
1
1
1
1
Value (overall)
29
11
10
9

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Veru with its peers
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Aardvark Therapeutics
NSQ:AARD
29
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Lipocine
NAQ:LPCN
39
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →